BioCentury | Oct 21, 2020
Product Development

UCSF’s virus-host protein interaction maps ID targets for COVID-19, future coronaviruses require hospitalization than new users of anti-COX-2...
BioCentury | Sep 25, 2020
Management Tracks

Lopes-Fernandes to lead BD for Ipsen; plus

...therapies (see Emerging Company Profile: “Both Sides of the TCR-antigen Coin”).Tomas Navratil will depart Nicox S.A. (Euronext:COX...
BioCentury | Jul 31, 2020
Distillery Therapeutics

Oral small molecule viral RNA polymerase inhibitor for parainfluenza virus vitro ; cell culture; mice LICENSING STATUS: Patent and licensing status unavailable PUBLICATION DETAILS: Cox...
BioCentury | Jul 17, 2020

Survey: biotechs adapting to COVID-19 era, optimistic about 2021

...with which people are working in our company, but across the industry is remarkable,” said Cox...
...disease will not. The biotech industry is the industry that offers the solutions,” said John Cox...
BioCentury | Jun 9, 2020
Management Tracks

Key to FDA’s COVID-19 drug reviews, Farley becomes permanent OID director

...Research. He has been serving as acting director since the departure last August of Edward Cox...
BioCentury | May 21, 2020
Emerging Company Profile

Repertoire bets on both sides of the TCR-antigen coin

...combined $220 million in venture funds (see “Flagship’s Repertoire Combines Cogen, Torque” ). CEO John Cox... understand from that repertoire, what their immune security is?” Formerly CEO of Bioverativ Inc., Cox...
...antigens and tethered to IL-15, is in Phase I testing for solid and hematological tumors. Cox...
BioCentury | Apr 24, 2020
Product Development

Stakeholders call for trial standardization as COVID-19 study influx burdens the system

...and a very large number of patients because expected death rates vary widely, said Edward Cox...
BioCentury | Apr 23, 2020
Product Development

First glimpse of controlled remdesivir data cast doubt on its COVID-19 treatment potential

...“As such, the study results are inconclusive.” During a webinar hosted by CTTI Thursday, Ed Cox...
BioCentury | Mar 13, 2020

Flagship’s Repertoire combines Cogen, Torque to pick antigens for immunotherapies

...includes fresh undisclosed funding raised in October. Repertoire will be helmed by Torque CEO John Cox...
BioCentury | Mar 13, 2020
Product Development

March 12 Quick Takes: WuXi AppTec’s Wuhan site back online; plus SOX relief, AZ, BMS, Nicox-Ocumesion, Tyligand-Context

...progression free survival vs. platinum-based chemotherapy. Nicox getting €15M, study funding from Ocumension Nicox S.A. (Euronext:COX...
Items per page:
1 - 10 of 1185